Strides Of India Said Holding Attractive Sale Opportunity With Its Agila Unit
This article was originally published in PharmAsia News
Executive Summary
India's Strides Arcolab reportedly is in a good position to gain a good price by selling its Agila Specialties cancer and antibiotics unit, according to sources.